Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and estramustine with thalidomide in treating patients who have prostate cancer previously treated with hormone therapy.

Key facts

Study ID

NCT00046826

Run by

Nuvance Health

Starts

2001-09-01

Expected to finish

2009-10-01

Last updated by the study team

2013-04-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Whittingham Cancer Center at Norwalk Hospital — Norwalk, Connecticut, United States
• Carl and Dorothy Bennett Cancer Center at Stamford Hospital — Stamford, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.